GlassScriptPhysician profile
Gary L Peterson
NPI 1932364924
$3,557.35
in general payments reported to CMS, 2019-2025
26 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $585 · 2021: $893 · 2022: $784 · 2023: $379 · 2024: $143 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $638.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $473.77 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $430.72 | 2019-2023 | |
| Lilly USA, LLC | $405.38 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.37 | 2019-2024 | Jardiance, Synjardy |
| Pfizer INC. | $289.87 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $278.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $277.91 | 2019-2023 | Steglatro, Belsomra |
| Amarin Pharma, INC. | $153.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.63 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $123.85 | 2019-2022 | |
| Abbott Laboratories | $102.13 | 2020-2022 | |
| Exact Sciences Corporation | $75.70 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $70.80 | 2019-2020 | |
| Medtronic, INC. | $61.92 | 2023-2024 | Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Amneal Pharmaceuticals LLC | $52.05 | 2022-2023 | Unithroid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $39.44 | 2023-2025 | Vivitrol, Vivitrol |
| Astellas Pharma US INC | $34.09 | 2020-2021 | |
| Grifols USA, LLC | $34.07 | 2020-2021 | |
| Amgen INC. | $34.00 | 2023-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $32.01 | 2022-2023 | Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.94 | 2021 | |
| Sanofi Pasteur INC. | $29.33 | 2019-2021 | |
| Esperion Therapeutics, INC. | $21.28 | 2020 | |
| Smith+Nephew, INC. | $19.22 | 2025 | Renasys Touch |
| E.R. Squibb & Sons, L.L.C. | $15.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.